NCT00504140View on ClinicalTrials.gov

Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

November 30, 1996

Primary Completion Date

November 30, 2007

Study Completion Date

March 31, 2009

Conditions

Osteosarcoma

Interventions

DRUG

Etoposide

100 mg/m\^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.

DRUG

Interferon Alpha

5x10\^6 mu/m\^2 Subcutaneously Daily for 5 Days

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Schering-Plough

All Listed Sponsors

collaborator

Schering-Plough

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER